NeoGenomics Executive and Leadership Team

Anthony Zook, the Chief Executive Officer at NeoGenomics, directs the company's overarching strategy and operational execution. Zook guides the expansion of NeoGenomics' network of cancer-focused genetic testing laboratories, ensuring services meet the needs of hospitals, pathologists, oncologists, and researchers across the United States. This leadership involves driving the integration of advanced cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, and molecular testing services. Anthony Zook oversees the strategic direction for enhancing diagnostic capabilities and supporting pharmaceutical clients' oncology programs. The Chief Executive Officer's focus remains on solidifying NeoGenomics' market position through innovation and operational excellence in genetic and molecular diagnostics.

Douglas Oort, the Executive Chairman & Chief Executive Officer at NeoGenomics, provides critical leadership and strategic oversight for the organization. Oort's role involves guiding the company's long-term vision and ensuring robust governance across its network of cancer-focused genetic testing laboratories. This executive leadership focuses on the strategic direction of NeoGenomics' operations, including the expansion and enhancement of its genetic and molecular testing services. Douglas Oort's responsibilities encompass driving growth initiatives and maintaining the company's commitment to serving hospitals, pathologists, oncologists, and researchers. The Executive Chairman & Chief Executive Officer ensures alignment with market demands and fosters an environment of continuous improvement in diagnostic capabilities.

George Cardoza, the Chief Financial Officer at NeoGenomics, manages the company's financial strategy and operations. Cardoza oversees all fiscal activities, including financial planning, budgeting, and reporting, ensuring the financial health of NeoGenomics' extensive network of cancer-focused genetic testing laboratories. This role is critical for supporting the company's growth in providing genetic and molecular testing services to hospitals, pathologists, oncologists, and researchers. George Cardoza directs financial resource allocation to advance cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, and molecular testing services. The Chief Financial Officer's expertise ensures sound financial management, enabling continued investment in diagnostic innovation and operational expansion across the United States.

Warren Stone, the President & Chief Operating Officer at NeoGenomics, drives the operational execution and strategic implementation across the company. Stone oversees the day-to-day operations of NeoGenomics' network of cancer-focused genetic testing laboratories, ensuring efficiency and quality in the delivery of genetic and molecular testing services. This leadership role encompasses managing the complex processes involved in cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, and molecular testing. Warren Stone directs efforts to support hospitals, pathologists, oncologists, and researchers, optimizing service delivery throughout the United States. The President & Chief Operating Officer's mandate is to enhance operational performance and support the company's growth objectives.

Michelle Backus, the Vice President, Enterprise Platforms and Interim Chief Technology Officer at NeoGenomics, spearheads the development and management of the company's technology infrastructure. Backus directs the enterprise platforms that support NeoGenomics' comprehensive genetic and molecular testing services, ensuring seamless integration and scalability for its network of laboratories. This leadership role is vital for enhancing the delivery of cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, and molecular testing. Michelle Backus oversees the technological strategies that empower hospitals, pathologists, oncologists, and researchers with advanced diagnostic tools. The Interim Chief Technology Officer's focus is on driving technological innovation to support NeoGenomics' mission in cancer diagnostics.

Jamie Plattt, the Chief Operations Officer at NeoGenomics, directs the operational efficiency and strategic deployment of resources within the company's laboratory network. Plattt oversees the critical functions supporting NeoGenomics' extensive genetic and molecular testing services, ensuring high standards of quality and throughput for cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, and molecular testing. This executive leadership focuses on optimizing laboratory workflows and supply chain management to effectively serve hospitals, pathologists, oncologists, and researchers across the United States. Jamie Plattt's responsibilities include driving operational improvements that enhance the company's capacity to deliver advanced cancer diagnostics. The Chief Operations Officer ensures seamless execution of services supporting patient care and research.

Derek Lyle, the Chief Medical Officer at NeoGenomics, provides essential medical and scientific leadership for the company's diagnostic services. Lyle guides the clinical strategy and ensures the scientific integrity of NeoGenomics' comprehensive genetic and molecular testing portfolio, including cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, and molecular testing. This role is pivotal in translating scientific advancements into clinical applications for hospitals, pathologists, oncologists, and researchers. Derek Lyle oversees the medical aspects of supporting pharmaceutical clients' oncology programs and ensures the highest standards of diagnostic accuracy. The Chief Medical Officer's expertise drives innovation in cancer diagnostics and supports the company's commitment to improving patient outcomes through advanced testing.